1. Innostellar Biotherapeutics

Innostellar Biotherapeutics was founded in 2020, focusing on the research, development, and manufacturing of innovative gene therapy drugs. To date, the company has established a GMP-compliant, scalable platform process for producing AAV products, with the capability to develop high-yield, high-quality gene therapy products at a controllable cost. Currently, the company has advanced five candidate molecules into clinical trials, being the first to initiate gene therapy clinical studies in three blinding eye disease indications. Among them, LX101 for treating RPE65 mutation-associated inherited retinal dystrophy (IRD) has entered Phase III clinical trials; LX102 for treating wet age-related macular degeneration has entered Phase II clinical trials; LX103 for treating X-linked retinoschisis has completed an IIT trial involving six patients, showing significant safety and efficacy.

2. RecoRNA

RECORNA was founded in December 2021 as an innovative drug research and development company that utilizes RNA-targeting editing technology to develop treatments for diseases that currently lack effective conventional therapies, aiming to address unmet clinical needs in genetic disorders caused by gene mutations, neurological diseases, and other disease areas. The company has established an independent intellectual property RNA editing platform capable of repairing and optimizing protein sequences and functions without permanently modifying the genome. Currently, RECORNA is leveraging its RNA editing platform to develop drugs in fields such as rare genetic diseases and metabolic disorders.

1. Phrontline Biopharma

Phrontline Biopharma was established in early 2022, focusing on the development of ADC drugs. Its proprietary technology platform covers four core technologies of ADC drugs (payload, linker, conjugation method, and antibody). Additionally, the company has independently developed site-specific and stoichiometric conjugation technology, with significantly higher conjugation uniformity than industry standards. It can introduce two different linker-payloads through two distinct conjugation techniques, enabling the combination of payloads with different mechanisms of action (MOA) to address single-payload resistance issues. Currently, multiple bispecific ADC pipelines are advancing rapidly. The core R&D project, TJ101, demonstrates superior tumor selectivity and growth inhibition effects compared to single-antibody ADC targeting the same antigen in various preclinical tumor models. Potential indications include lung cancer, head and neck cancer, and other solid tumors.

2. Puling Biopharmaceutical

Puling Biopharmaceutical (Suzhou) Co., Ltd. was founded in 2021 as an innovative ADC biotechnology company dedicated to developing the next generation of precise and flexible drug delivery systems. The company aims to establish a drug conjugation and delivery platform to bring its proprietary "First in class and Best in class" products to the global market. The company’s technical lead has over two decades of ADC industry experience, covering the entire process from early drug discovery to clinical trials across multiple disciplines. Leveraging the deep industrial track record of its technical team and robust capital support, the company will make full use of resources in both China and the U.S., collaborate on research and development, and gradually promote its technologies and drugs globally to benefit cancer patients worldwide.

Maikang Bio

Maikang Bio was founded in 2016 as a global biopharmaceutical company dedicated to the research, development, production, and commercialization of innovative vaccines and novel adjuvants. The company focuses on the R&D, production, and commercialization of innovative human and veterinary (including pet) vaccines. Based on internationally leading platforms for novel adjuvants, recombinant proteins, and immunological evaluation, it has established a pipeline of significant innovative vaccine products. With nearly 20 types of adjuvant raw materials, the company has developed three mature delivery systems and over 10 composite formulations, forming a vertical industrial chain from the R&D and production of adjuvant raw materials to the development and application of adjuvant formulations. Currently, the company has diversified its product R&D pipelines across infectious, allergic diseases, and cancer fields, including multiple preventive vaccines for major infectious diseases and therapeutic vaccines in areas such as HPV infection, allergic diseases, and cancer. Two of these have entered clinical trial stages.

Aoda Bio

Aoda Biotech was established in March 2017, focusing on the research and development of innovative peptide drugs, covering types such as viral fusion inhibitors, targeted anti-tumor peptides, and antimicrobial peptides. Peptides are easy to synthesize, optimize, modify, and combine, allowing for rapid determination of medicinal value; compared with large-molecule proteins, peptide chemical synthesis technology is mature; compared with small-molecule drugs, peptides have less dosage, better efficacy, stronger specificity, higher selectivity, and fewer side effects. The company’s long-acting peptide drugs, through various modifications, extend the drug's half-life by up to dozens of times; the dosing frequency decreases from once to three times daily to once a week or once every two weeks, greatly benefiting patients.

Anticodon Bio

Antikang Biotech is an innovative pharmaceutical company focused on respiratory infections and pain management. It has established high technical barriers at various stages of new drug creation, including innovative drug design and synthesis, DMPK technology research and application, and the research and development of advanced formulations for special populations. The company has developed a small-molecule innovative therapeutic drug R&D system based on metabolic differentiation. In addition to its anti-influenza new drug pipeline featuring Madenoxavir (ADC189), Antikang's product pipeline also includes several innovative drugs targeting respiratory pathogens, such as ADC789 suspension for respiratory syncytial virus (RSV) and ADC101 suspension, a novel anti-mycoplasma super-antibiotic. The proceeds from this funding round will be used for preclinical and clinical development of the company’s core product pipelines, particularly to accelerate the pediatric clinical trials and commercialization progress of its self-developed Class 1 anti-influenza new drug, Madenoxavir (code name: ADC189), in tablet and granule forms.

1. Micro-Evolution Healthcare

MicroEvolution Med is a cross-species tumor gene therapy service provider established in November 2023. It pioneered the miRNA repair therapy mediated by plant RDR1 protein, which utilizes the expression system of plant genes to mediate miRNA repair in human tumor cells, thereby suppressing tumor growth. This therapy offers new solutions for clinical needs involving recurrent and refractory cases with no available treatment options, demonstrating broad applicability and significant market potential.

2. Lymo Bio

Laymon Biotherapeutics is a clinical-stage immunometabolism innovative drug research and development company, focusing on the R&D, production, and commercialization of novel cancer immunotherapy drugs. The company has established a proprietary technology platform for the discovery, development, and production of biologic macromolecule drugs and novel immunotherapy cell-based drugs with independent intellectual property rights. Meanwhile, by leveraging cutting-edge artificial intelligence (AI) technology to iteratively upgrade existing drugs, it has developed three core drug pipelines: metabolically reprogrammed biologic macromolecule drugs, anti-exhaustion cell therapy drugs, and super-factor drugs. Among them, the metabolic-enhanced CAR-T cell therapy is currently undergoing IIT clinical research, successfully enrolling and treating over 20 adult patients with relapsed/refractory leukemia/lymphoma, all achieving complete remission (CR) and being discharged. Additionally, this therapy requires an extremely low drug dosage, shortens the production cycle, significantly reduces CAR-T manufacturing costs, and is expected to drastically lower the originally "astronomical" price of cell therapy drugs, offering the possibility of future inclusion in the medical insurance catalog.

Rendakangjian

Renda Health was established in September 2022. Using China's first biosynthesis technology, it successfully developed a high-purity, high-activity anti-Alzheimer's disease drug—Huperzine A API. The successful breakthrough of this technology not only solved the industry bottleneck issues of scarce resources in traditional plant extraction, low activity in chemical synthesis products, and significant pollution, but also resulted in more than ten invention patents.

Arthur Pharmaceuticals

Arthur Pharmaceuticals, established in March 2020, focuses on the development, production, and sales of high-end drugs, committed to developing top-tier generic drugs and innovative drugs with global leading advantages. Relying on decades of profound experience in the pharmaceutical industry and a global perspective, the company has established three major research and development centers worldwide. In fields such as cardiovascular drugs, nephrology drugs, and steroid drugs, Arthur Pharmaceuticals possesses several internationally leading core technologies that fill gaps within China.

The funds raised from this round of financing will be mainly used in three key areas: First, the construction of active pharmaceutical ingredient (API) production lines that meet the standards of China, the United States, and the European Union. This will help enhance the company's production capacity and product quality to meet the global demand for high-quality APIs. Second, the promotion of R&D for distinctive high-end formulation products and international market product registrations, accelerating the launch of new drugs and broadening the company’s product portfolio. Third, expediting the U.S. FDA application process for the continuous production of oral solid dosage generic drugs, further strengthening the company’s competitiveness in the international market.

Recommended with Charge

●Recommended 15 Classic Books for Systematic Learning of Biopharmaceutical CMC (Free Download)

●How are the performances of CDMOs in China during this cold winter?

●The Bioprocess Industry "Gathers Momentum", Breakthroughs in Key Process Points!

●An Analysis: Requirements of the U.S. FDA for Pharmaceutical Process Development

●In-depth Review of Nucleic Acid Drugs

●40 Stem Cell Therapy Companies and Technology Pipelines

● A Comprehensive Overview of 42 ADC Drug Companies in China

● A Glimpse of Global Layout Bispecific ADC Enterprises

●The Four Classic Site-Specific Conjugation Technologies of ADC

● Stem Cell Drug Development: Quality by Design (QbD)

●A Brief Discussion on the CMC Research Focus at Each Stage of Innovative Drugs

✦

Boutique Conference

✦

✦

High-Quality Community

✦

✦

Project Roadshow

✦

Scan the QR code to follow us

Reply in the background "Reader Group"，Let's chat with the小伙伴们 in the biopharmaceutical industry~"

Forward, like, and check. Can you arrange it?